Ares Financial Consulting’s Olema Pharmaceuticals OLMA Stock Holding History

Ares Financial Consulting’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$300	Buy	+24	New	+$321	﹤0.01%	1108

Other funds holding OLMA

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Ares Financial Consulting's OLMA Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Olema Pharmaceuticals (OLMA) in Q2 2026: 24 shares worth $300. The stake represents ﹤0.01% of the portfolio and ranks #1108 among its holdings.

10 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

Ares Financial Consulting held 24 shares of Olema Pharmaceuticals worth $300 as of Q2 2026.
Olema Pharmaceuticals was a new Ares Financial Consulting position in Q2 2026.
Olema Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1108 holding.
10 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.